However, notably, in the AZD2014-treated tumours, the expression of the glucose transporter GLUT1 (also known as SLC2A1) remained high in Region A even though there was generally a reduction following AZD2014 treatment in Region B (Fig. 5A,D,E). Here, SLC2A1 is linked to neoplasm.